Month: May 2024

ProQR Announces First Quarter 2024 Operating and Financial Results

Written by Customer Service on May 9, 2024. Posted in Public Companies.

Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled for May 22, 2024 Continued strength of leading IP estate around ADAR-mediated RNA editing highlighted with successful defense of challenge to granted patent in Europe €102.7 million as of end of Q1 providing runway into mid-2026LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for...

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Written by Customer Service on May 9, 2024. Posted in Public Companies.

Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERYMedtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pumpCambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announced a research collaboration with Medtronic plc (NYSE: MDT), a global leader in healthcare technology, to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump. This new insulin has the potential to bring significant advancements...

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Written by Customer Service on May 9, 2024. Posted in Public Companies.

Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ETCAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the first...

Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

Written by Customer Service on May 9, 2024. Posted in Public Companies.

Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensors Rapid enzymatic synthesis continues to improve iqDNA performance through process development and the identification of novel structural elementsData on cell-targeted LNP (ctLNP) in vivo delivery of therapeutic transgenes to T cells to be discussed in an oral presentation on Saturday, May 11CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms as well as its enzymatic synthesis manufacturing at the American Society of Gene and Cell...

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

Written by Customer Service on May 9, 2024. Posted in Mergers And Acquisitions.

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024 financial results call today at 8:00 a.m.NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approximately $525 million in cash including estimated transaction costs. ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones...

GFG Signs Binding LOI with Patriot Gold to Sell its Rattlesnake Hills Gold Project

Written by Customer Service on May 9, 2024. Posted in Mergers And Acquisitions.

SASKATOON, Saskatchewan, May 09, 2024 (GLOBE NEWSWIRE) — GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announces the signing of a binding letter of intent (the “LOI”) for the sale of its 100% owned Rattlesnake Hills Gold Project (the “Project”) to Patriot Gold Vault Ltd., (“Patriot”). Under the terms of the LOI, which will be formalized by a definitive agreement between the parties within forty-five (45) days (the “Transaction”), Patriot will pay GFG an aggregate consideration of approximately C$3.3 million. “We are excited to announce our agreement with Patriot for the sale of our Rattlesnake Hills Gold Project,” stated Brian Skanderbeg, President and CEO of GFG. “The Patriot team’s impressive track record gives us great confidence in their ability to drive the Project forward from both an exploration...

GoHealth Reports First Quarter 2024 Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

CHICAGO, May 09, 2024 (GLOBE NEWSWIRE) — GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three months ended March 31, 2024. First Quarter HighlightsFirst quarter 2024 net revenues of $185.6 million, a slight increase compared to $183.2 million in the prior year period. First quarter 2024 Submissions of 216,148, a 2,503 increase compared to 213,645 Submissions in the prior year period. First quarter 2024 net loss of $21.3 million, an improvement of $1.2 million compared to $22.5 million in the prior year period. First quarter 2024 Adjusted EBITDA(1) of $26.9 million, a decrease of $1.9 million compared to $28.8 million in the prior year period. First quarter 2024 trailing twelve months (“TTM”)...

Vantage Drilling International Ltd. Reports First Quarter 2024 Results

Written by Customer Service on May 9, 2024. Posted in Earnings Releases And Operating Results.

DUBAI, United Arab Emirates, May 09, 2024 (GLOBE NEWSWIRE) — Vantage Drilling International Ltd. (“Vantage” or the “Company”) reported a net loss attributable to controlling interest of approximately $2.9 million or $0.22 per diluted share for the three months ended March 31, 2024, as compared to a net loss attributable to controlling interest of $2.3 million or $0.17 per diluted share for the three months ended March 31, 2023. As of March 31, 2024, Vantage had approximately $67.0 million in cash, including $10.8 million of restricted cash, compared to $84.0 million in cash, including $10.8 million of restricted cash, at December 31, 2023. At March 31, 2024, Vantage maintained $11.1 million of cash pre-funded by our Managed Services customers to address near-term obligations. Excluding cash used in connection with our...

Arhaus Announces First Quarter 2024 Financial Results

Written by Customer Service on May 9, 2024. Posted in Public Companies.

Net Revenue of $295 million, Net Income of $15 million, and Adjusted EBITDA of $29 million Reaffirming Full Year 2024 Outlook BOSTON HEIGHTS, Ohio, May 09, 2024 (GLOBE NEWSWIRE) — Arhaus, Inc. (NASDAQ: ARHS; “Arhaus” or the “Company”), a rapidly growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 HighlightsNet revenue of $295 million Comparable growth(1) of (9.5)% Net and comprehensive income of $15 million Adjusted EBITDA of $29 million2024 Outlook ReaffirmedNet revenue of $1.33 billion to $1.37 billion Comparable growth(1) of (4.0)% to (2.0)% Net and comprehensive income of $95 million to $105 million Adjusted EBITDA of $185 million to $200 millionCEO Comments John Reed, Co-Founder and Chief...

Form 8.3 – Darktrace Plc

Written by Customer Service on May 9, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Jupiter Fund Management Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of Offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Darktrace plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date dealing undertaken: For an opening position disclosure,...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals